Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO)-Reference-Cited by-同舟云学术

Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO)

Published:2008 Issue:5 Volume:31 Page:237-241
ISSN:1423-0240
Container-title:Onkologie
language:en
Short-container-title:Onkologie

Author:

Hartmann Jörg Thomas,Pintoffl Jan Peter,Kröning Hendrik,Bokemeyer Carsten,Holtmann Martin,Höhler Thomas

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,Hematology,General Medicine

Reference30 articles.

1. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

2. Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

3. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

4. Phase III Study of Weekly High-Dose Infusional Fluorouracil Plus Folinic Acid With or Without Irinotecan in Patients With Metastatic Colorectal Cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986

5. Bevacizumab in Combination With Fluorouracil and Leucovorin: An Active Regimen for First-Line Metastatic Colorectal Cancer

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Introduction;Third Generation EGFR Inhibitors;2019

2. Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine;Internal Medicine;2017

3. Kinases inhibitors in lung cancer: From benchside to bedside;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2016-08

4. Inhibition of SN-38 glucuronidation by gefitinib and its metabolite;Cancer Chemotherapy and Pharmacology;2015-04-28

5. SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model;Neoplasma;2014